Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design.

Chaft, Jamie E., Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, and Gregory J. Riely. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.

Chaft, Jamie E., et al. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.